An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 10, 2017

Primary Completion Date

March 5, 2019

Study Completion Date

March 19, 2020

Conditions
Melanoma
Interventions
DRUG

REGN2810

REGN2810 treatment

Trial Locations (8)

11000

Military Medical Academy, Belgrade

6500 HB

Radboud University Medical Center, Nijmegen

03080

Seoul National University Hospital, Seoul

05505

Asan Medical Center, Seoul

135-710

Samsung Medical Center, Seoul

Unknown

Severance Hospital-Yonsei University College of Medicine, Seoul

Guy's Hospital and St. Thomas NHS Foundation Trust, London

0X3 7LE

Churchill Hospital, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY